Search Follow us

ReNeuron Group (RENE)

Business description

ReNeuron is a UK biotech company developing allogeneic cell therapies: CTX neural stem cell products for stroke disability (Phase IIb) and human retinal progenitor cells for retinitis pigmentosa (Phase I/II).

Stock data

Market cap.£15m
Last close47.50p
High / Low (52 weeks)103.5p / 47.5p
Stock market listingLN
Forecast net cash (£m)19.7
Forecast gearing ratio (%)N/A
TeamHealthcare
SectorPharmaceuticals & healthcare

Price performance

%1m3m12m
Actual(7.8)(21.5)(54.1)
Relative *(10.7)(23.7)(53.4)

* % Relative to local index

Other companies in sector Show

4SC aap Implantate
Aastrom Biosciences AB Science
Abcam Abivax SA
Ablynx Abzena
Acacia Pharma Acarix
Acerus Pharmaceuticals Achillion Pharmaceuticals
Acorda Therapeutics Actinium Pharmaceuticals
Actinogen Medical Active Biotech
Acucela Addex Therapeutics
Adherium ADL Bionatur Solutions
Adocia Advanced Medical Solutions
Aegerion Pharmaceuticals Aeterna Zentaris
AFT Pharmaceuticals Agennix
Akari Therapeutics Alchemia
Alexza Pharmaceuticals Algeta
Alimera Sciences ALK Abello
Alkermes Allergy Therapeutics
Alliance Pharma Allium Medical Solutions
Alnylam Pharmaceuticals Amarantus BioScience
Amarin Amplifon
AmpliPhi Biosciences Angle
Animalcare Group Anteo Diagnostics
Anthera Pharmaceuticals Antibe Therapeutics
Aratana Therapeutics Ardea Biosciences
Ardelyx Arena Pharmaceuticals
arGEN-X Argos Therapeutics
Ariad Pharmaceuticals Arix Bioscience
Ark Therapeutics Group ArQule
Array BioPharma Arrowhead Research Corporation
Ascendis Pharma ASIT biotech
ASLAN Pharmaceuticals Astex Pharmaceuticals
Athersys Atossa Genetics
Auris Medical Holding Avacta Group
Avalanche Biotechnologies AVEO Pharmaceuticals
Avita Medical Avivagen
Balda Basilea Pharmaceutica
Bavarian Nordic Bellus Health
Benitec Biopharma BioCryst Pharmaceuticals
BioInvent BioLargo
BioLight Life Sciences BioLineRx
BiondVax Pharmaceuticals Bionomics
Bionor Pharma BioPorto Diagnostics
Biota Holdings Biotie Therapies Corp
Biotron Bluebird Bio
Bone Therapeutics Bonesupport
BrainStorm Cell Therapeutics Brighter
BTG C4X Discovery Holdings
Caladrius Biosciences Can-Fite BioPharma
CannTrust Holdings Cantargia
Capstone Therapeutics Carmat
CASI Pharmaceuticals Cell Therapy
Celldex Therapeutics Cellectis
Cellular Biomedicine Group Celyad
Cerulean Pharma Circadian Technologies
Circassia Pharmaceuticals Clal Biotechnology Industries
Clavis Pharma Cleveland BioLabs
Clinigen Group Clinuvel
CO.DON CollPlant Holdings
Consort Medical Corium International
Crescendo Crossject
CSL Curetis NV
Curis Cytori Therapeutics
Cytos Biotechnology CytRx Corporation
DBV Technologies Dechra Pharmaceuticals
Deinove Delcath Systems
Deltex Medical Derma Sciences
Destiny Pharma DiaSorin
Diaxonhit e-Therapeutics
Egalet Corporation EKF Diagnostics
Elbit Medical Technologies Ellex Medical Lasers
Emergent BioSolutions Endocyte
Epigenomics Ergomed
Erytech Pharma Esperion Therapeutics
Evotec Exact Sciences
Exelixis Expedeon
EyeGate Pharmaceuticals Factor Therapeutics
Formycon Forward Pharma
Fresenius SE & Co. KGaA Futura Medical
Galapagos Galmed Pharmaceuticals
Genedrive Genfit
Genkyotex Genmab
GeoVax GI Dynamics
Gilead Sciences GNI Group Ltd
GW Pharmaceuticals Halozyme Therapeutics
Heat Biologics Inc. Heidelberg Pharma
Herantis Pharma Horizon Discovery
Hutchison China MediTech Hybrigenics
iCo Therapeutics Idenix
Immune Pharmaceuticals Immunicum
Immunodiagnostic Systems Holdings Immunovia
ImmuPharma Immutep
Imprimis Pharmaceuticals Imugene
Incyte Corporation Infinity Pharmaceuticals
InflaRx InMed Pharmaceuticals
Innate Pharma Insmed
Intec Pharma International Stem Cell
Invion Ion Beam Applications
Ipsogen Iridex
Ironwood Pharmaceuticals Islet Sciences
Ixico Japan Tobacco
KaloBios Pharmaceuticals Kane Biotech
Karolinska Development Kazia Therapeutics
Keryx Biopharmaceuticals Kiadis Pharma
Laboratorios Farmacéuticos ROVI LCA-Vision
LeMaitre Vascular Lifeline Scientific
LifeWatch Ligand Pharmaceuticals
Lipocine Lombard Medical Technologies
MagForce Mast Therapeutics
Medcom Tech Medicago
MediciNova Medicure
Medigene MedinCell
Medivir Merrimack Pharmaceuticals
Merrion Pharmaceuticals Mesoblast
MethylGene MGC Pharmaceuticals
Midatech Pharma MISSION Therapeutics
Molecular Partners MolMed
Mologen Momenta Pharmaceuticals
MorphoSys Nanobiotix
Nanosonics Navidea Biopharmaceuticals
Nektar Therapeutics NeoStem
Neovacs NetScientific
NeuroVive Pharmaceutical Newron Pharmaceuticals
Nexstim NicOx
NMC Health NorDiag
Nordion NovaBay Pharmaceuticals
Novacyt NPS Pharmaceuticals
Nuevolution Ocata Therapeutics
Omega Diagnostics Group Omeros Corporation
OncoGenex Pharmaceuticals Oncology Venture
Oncolytics Biotech Inc OncoMed Pharmaceuticals
Onconova Therapeutics Oncothyreon
Onxeo Onyx Pharmaceuticals
Opexa Therapeutics OPMEDIC Group
Optos Orexigen Therapeutics
Orexo Orgenesis
Oryzon Genomics OSE Immunotherapeutics
Ossur OvaScience
OWL Oxford BioMedica
Oxford Immunotec Pacific Edge
Paion Paladin Labs
Patheon PBKM
PDL BioPharma Pharmacyclics
PharmaMar Pharmaxis
Pharming Group Photocure
Phylogica Pixium Vision
Pluristem Therapeutics Prescient Therapeutics
Probiodrug ProMetic Life Sciences
Prosensa Proteome Sciences
PsiOxus QRxPharma
Quantum Genomics Quantum Pharmaceuticals
Race Oncology RedHill Biopharma
Regeneus Relmada Therapeutics
Resverlogix REVA Medical
Rovi RXi Pharmaceuticals
Sangamo BioSciences Sarepta Therapeutics
Sartorius Scancell
Selvita Shield Therapeutics
Shire Sierra Oncology
Silence Therapeutics Simavita
Sinclair Pharma Sirtex Medical
Skyepharma Smith & Nephew
Sobi Sosei Group Corporation
Source Bioscience SQI Diagnostics
Stallergenes StemCells
Stentys Stratec Biomedical
Sucampo Pharmaceuticals Sunesis Pharmaceuticals
Surgical Innovations Sygnis
SymBio Pharmaceuticals Synairgen
Synergy Health Synta Pharmaceuticals
T‐cell cancer therapies Targovax
TearLab Corp Tekmira
Telix Pharmaceuticals TESARO
Theraclion Therapix Biosciences
Threshold Pharmaceuticals ThromboGenics
TiGenix Tissue Regenix
Tissue Therapies Titan Pharmaceuticals
Tonix Pharmaceuticals Topotarget
Touchstone Innovations Transgene
Trillium Therapeutics True Leaf
TruScreen TxCell
UCB UDG Healthcare
uniQure NV Universal Biosensors
VBI Vaccines Vectura
Verastem Verisante Technology
Vernalis Verona Pharma
Vertex Pharmaceuticals Viralytics
ViroPharma Vivalis
Vivus VolitionRx
WaferGen Biosystems Xbrane Biopharma
Xencor Zafgen
Zealand Pharma Ziopharm Oncology

Company news

Proactive news snapshot: ReNeuron Group, DP Poland, Minds + Machines …

Fri, 04 May 2018 14:57:10 GMT

ReNeuron making good progress with all of its key therapeutic programmes

Tue, 31 Oct 2017 15:54:43 GMT

ReNeuron Group head of research to present encouraging early data on potential ...

Fri, 04 May 2018 07:18:45 GMT

ReNeuron jumps at opening bell as it gets green light to begin second part of ...

Wed, 08 Nov 2017 08:20:17 GMT

ReNeuron receives approval from US authorities to kick off phase IIb stroke trial

Thu, 14 Dec 2017 08:05:36 GMT

Investment summary

ReNeuron is focused on three cell therapy-based programs. The CTX neural stem cell program has demonstrated positive response rates in key measures were sustained after extended follow-up. ReNeuron will be starting the placebo-controlled Phase IIb trial in chronic stroke disability in H218 with data expected in early 2020. ReNeuron also has the hRPC (human retinal progenitor cells) program for retinitis pigmentosa (currently in Phase I/II) and will also be starting a Phase IIa trial in cone-rod dystrophy. The exosome platform (generated from the CTX cell line) is a further source of products and business development for ReNeuron.

Last updated on 01/02/2019

Y/E Mar Revenue (£m) EBITDA (£m) PBT (£m) EPS (p) P/E (x) P/CF (x)
2017A 0.9 (19.8) (18.2) (0.49) N/A N/A
2018A 0.9 (20.2) (21.0) (55.66) N/A N/A
2019E 0.0 (23.6) (22.0) (55.17) N/A N/A
2020E 0.0 (27.2) (27.2) (70.94) N/A N/A

Last updated on 24/01/2019

Latest video

Executive Interview - ReNeuron

Industry outlook

Limited drug development has targeted chronic stroke to date, which is the area in which ReNeuron is attempting to demonstrate a meaningful reduction in disability. If shown, it would offer a compelling case for further development and/or partnering.

Last updated on 01/02/2019

Key management

John Berriman, Chairman
Olav Hellebø , CEO
Michael Hunt, CFO
John Sinden, Chief Scientific Officer

Company address

Pencoed Business Park
Pencoed
Bridgend
CF35 5HY
United Kingdom
+44 (0)1483 302560
View website